In This Section

Program

Please note that this special conference will take place as an in-person event in Montrealand will not live-stream content for virtual participation. The conference content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, September 24 

Thursday, September 25 

Friday, September 26 

Saturday, September 27 

Wednesday, September 24

REGISTRATION

3-7 p.m. | Grand Salon Foyer

WELCOME AND Keynote Lecture

6-6:50 p.m. | Grand Salon Opera AB

  • 6 p.m. | Welcome and Introduction of Keynote Speaker
    Sandra Demaria, Weill Cornell Medical College, New York, New York
  • 6:05 p.m. | Autoimmunity and Cancer: Informing each other through patient-oriented studies  
    Virginia Pascual, Weill Cornell Medical College, New York, New York

Reception 

7-9 p.m. | Grand Salon Opera C

Thursday, September 25

Continental Breakfast and Networking Roundtables

7-8 a.m. | Grand Salon Foyer

Plenary Session 1: Immune Tolerance and Surveillance: Implications for Cancer and Autoimmunity

8-10 a.m. | Grand Salon Opera AB

Session Chair: Mark Anderson, University of California, San Francisco, California

  • 8 a.m. | Lymphatic transport and T cell recirculation maintains chronic responses in cancer
    Amanda Lund, NYU Langone Perlmutter Cancer Center, New York, New York
  • 8:30 a.m. | Dissecting immune tolerance through outliers 
    Mark Anderson, University of California, San Francisco, California
  • 9 a.m. | Regulation of CD8 T cell fates in cancer
    Chen Dong, Westlake University, Hangzhou, Zhejiang, China 
  • 9:30 a.m. | Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy*
    Chunbo He, Affiliated Provincial Hospital of Fuzhou University, Fuzhou University, Fuzhou
  • 9:45 a.m. | Relationship between CD4⁺ T cells and cancer stem cells in squamous cancers of the oro-esophageal tract*
    Maxence Plateau, University of Sherbrooke, Sherbrooke, QC, Canada

Break 

10-10:20 a.m. | Grand Salon Foyer

Plenary Session 2: Innate Sensing and Type I Interferon Response in Cancer and Autoimmune Disease 

10:20 a.m.–12:20 p.m. | Grand Salon Opera AB

Session Chair: Sandra Demaria, Weill Cornell Medical College, New York, New York

  • 10:20 a.m. | Therapeutic modulation of nucleic acids-induced immune activation
    Sandra Demaria
  • 10:50 a.m. | Targeting inflammatory memory and chronic interferon signaling in cancer immunotherapy 
    Andy J. Minn, University of Pennsylvania, Philadelphia, Pennsylvania
  • 11:20 a.m. | A genome-wide look at tumor immunoediting  
    Judy Lieberman, Harvard Medical School, Boston, Massachusetts
  • 11:50 a.m. | Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance*
    Katie Owen, Peter MacCallum Cancer Centre, Melbourne, Australia
  • 12:05 p.m. | Tumor-derived Complement Factor B drives tumor growth and anti-PD-1 resistance in STK11-mutant lung adenocarcinoma*
    Edwin Yau, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Free time / Lunch on your own 

12:20-2:20 p.m. 

Plenary Session 3: Epigenetic and Genetic Regulation of Cancer Immunity and Autoimmunity  

2:20-4:20 p.m. | Grand Salon Opera AB

Session Chair: Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

  • 2 p.m. | Unmasking epigenetically hidden targets for adoptive T cell immunotherapy of ovarian cancer
    Kunle Odunsi
  • 2:50 p.m. | Epigenetic regulation of T cells in autoimmunity and anti-cancer immunity
    Maureen Su, UCSF – University of California San Francisco, California
  • 3:20 p.m. | Elad Ziv, UCSF – University of California San Francisco, San Francisco, California
  • 3:50 p.m. | Targeting PRMT5 to modulate endogenous retroviruses expression in melanoma*
    Simon Milette, Yale University, New Haven, Connecticut
  • 4:05 p.m. | Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy*
    Maria Goicoechea, The Institute of Cancer Research, United Kingdom

Break 

4:20-4:40 p.m.

Plenary Session 4: Adaptive Immune Regulation in Cancer and Autoimmunity

Organized by the Cancer Immunology (CIMM) Working Group

4:40-5:45 p.m. | Grand Salon Opera AB

Session Chair: Abigail Overacre, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

  • 4:40 p.m. | Functional fate of Foxp3+ regulatory T cells in the tumor microenvironment
    Ciriaco A. Piccirillo, Research Institute of McGill University, Montreal, Canada
  • 5:05 p.m. | Spatial Instruction of Tissue T Cell Immunity
    Miguel Reina-Campos, La Jolla Institute for Immunology, La Jolla, California
  • 5:30 p.m. | Targeting PAR-2 improves tumor antigen presentation and primes the immune system for anti-PD-1 immunotherapy*
    Samya Aouad, CRCHUM, Montreal, Canada

Poster Session A and Reception 

6-8 p.m. | Grand Salon Opera C

Friday, September 26

 

Continental Breakfast and Networking Roundtables

7-8 a.m. | Grand Salon Foyer

Plenary Session 5: Therapeutics at the Intersection of Cancer and Autoimmunity 

8:00-9:30 a.m. | Grand Salon Opera AB

Session Chair: John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

  • 8 a.m. | Endocrine organs in the crosshairs of the immune system
    Zoe Quandt, University of California, San Francisco, California
  • 8:30 a.m. | Immune checkpoint-inhibitor associated myocarditis: From mouse to humans
    Javid Moslehi, University of California, San Francisco, California
  • 9 a.m. | Disrupting TACI signaling to restore immune balance: Harnessing translational opportunities at the intersection of cancer and autoimmunity*
    Yong Sheng, QIMR Medical Research Institution, Brisbane, Australia
  • 9:15 a.m. | Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice*
    Camille Hansen, University of Utah, Salt Lake City, Utah

Break 

9:30-9:50 a.m. | Grand Salon Foyer

Plenary Session 6: Role of Microbiota in Immunologic Fitness  

9:50-11:35 a.m. | Grand Salon Opera AB

Session Chair: Sandra Demaria, Weill Cornell Medical College, New York, New York

  • 9:50 a.m. | Reprogramming the tumor–immune microenvironment: From stromal circuits to engineered microbial immunotherapies
    Laurence Zitvogel, Gustave Roussy, Paris, France   
  • 10:20 a.m.| Probiotic neoantigen delivery vectors for precision cancer immunotherapy
    Nicholas Arpaia, Columbia University Irving Medical Center, New York, New York
  • 10:50 a.m. | Lifestyle induced susceptibility of immune related adverse events
    Abigail Overacre, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
  • 11:20 a.m. | Impact of gut microbiota on response to Bacillus Calmette-Guérin immunotherapy in bladder cancer: Towards a predictive molecular model*
    Marine Boireau, Faculty of Medicine, Université Laval, Québec, Canada

Break 

11:35- 11:45 a.m.

Panel Discussion: Modeling Immune-Related Adverse Events

11:45 a.m. – 12:30 p.m. | Grand Salon Opera AB

Session Chair: Javid Moslehi, University of California, San Francisco, California

  • 11:45 a.m. | Opportunities and obstacles in modeling immune-related adverse events
    Arabella Young, University of Utah, Salt Lake City, Utah – [R]
  • Panelist
    Zoe Quandt, University of California, San Francisco, California
    David E. Gerber, University of Texas Southwestern Medical Center, Dallas, Texas
    Lily Pao, Johnson & Johnson Innovative Medicine, Cambridge, Massachusetts
    Chloe Villani, Massachusetts General Hospital (MGH) Center for Cancer Research, Boston, Massachusetts
    Arabella Young, University of Utah, Salt Lake City, Utah – [R]

Free time / Lunch on your own 

12:30 – 2:30 p.m.

Plenary Session 7 : CD8 T cells in Cancer and Autoimmunity 

2:30-4:30 p.m. | Grand Salon Opera AB

Session Chair: Ana C. Anderson, Harvard Medical School and Brigham and  Women’s Hospital, Boston, Massachusetts

  • 2:30 p.m. | Mechanisms of TCF1 regulation of stem-like T cells in cancer                                    and autoimmunity
    Ana C. Anderson, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
  • 3 p.m. | E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania 
  • 3:30 p.m. | T cell stemness and differentiation in autoimmunity and cancer  
    Andrea Schietinger, Memorial Sloan-Kettering Cancer Center, New York, New York 
  • 4 p.m. | Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)*
    Zeynep Kosaloglu-Yalcin, La Jolla Institute for Immunology, La Jolla, California
  • 4:15-4:30 p.m. | Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade*
    Kristen Pauken, The University of Texas MD Anderson Cancer Center, Houston, Texas

Break 

4:30-4:50 p.m. | Grand Salon Foyer

Plenary Session 8: Interplay of B and T cells in Cancer and Autoimmunity 

4:50-6:20 p.m. | Grand Salon Opera AB

Session Chair: Amanda Lund, NYU Langone Perlmutter Cancer Center, New York, New York

  • 4:50 p.m. | Modulating B and T cell interactions within and outside of tertiary lymphoid structures for improved anti-tumor immunity  
    Tullia Bruno, University of Pittsburgh, Pittsburgh, Pennsylvania 
  • 5:20 p.m. | B cell checkpoints as regulators of tumor immunity and self-tolerance
    Llyod Bod, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
  • 5:50 p.m. | B cell infiltration and clonal expansion in tertiary lymphoid structures: insights from intravital microscopy*
    Gabrielle Rowe-Brown, Johns Hopkins All Children’s Hospital, Saint Petersburg, Florida
  • 6:05 p.m. | Single‑cell profiling of tumor‑infiltrating B cells reveals autoantibody repertoires and potential cross-talk with T cells*
    Mikiya Takata, The University of Tokyo, Tokyo, Japan

Poster Session B and Reception 

6:30-8:30 p.m. | Grand Salon Opera C

Saturday, September 27

Continental Breakfast and Networking Roundtables

7-8 a.m. | Grand Salon Foyer

Keynote Address

8-8:45 a.m. | Grand Salon Opera AB

  • 8 a.m. | Introduction of Keynote Speaker
    Ana Anderson, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
  • 8:05 a.m. | Targeting Tregs in tumors
    Dario AA Vignali, University of Pittsburgh, Pittsburgh, Pennsylvania

Plenary Session 9: Targeting Regulatory T cells in the Tumor Microenvironment and in Autoimmunity  

8:50-10:20 a.m. | Grand Salon Opera AB

Session Chair: Dario AA Vignali, University of Pittsburgh, Pittsburgh, Pennsylvania

  • 8:50 a.m. | From concept to cure: Developing TregSight for precision immunotherapy 
    Billur Akkaya, Ohio State University, Columbus, Ohio 
  • 9:20 a.m. | CAR-Treg adoptive immunotherapy to treat autoimmune disease
    Jeff Bluestone, University of California, San Francisco, California 
  • 9:50 p.m. | Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression*
    Maud Charpentier, Weill Cornell Medical College, New York, New York

Break

10:05-10:25 a.m. | Grand Salon Foyer

Spotlight on Emerging Science

10:25-11:25 a.m. | Grand Salon Opera AB

Session Chair: Sandra Demaria, Weill Cornell Medical College, New York, New York

  • 10:25 a.m. | CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC*
  • Richard Pestell, Pennsylvania Cancer and Regenerative Medicine Center, Baruch S. Blumberg Institute, Wynnewood, Pennsylvania
  • 10:40 a.m. | Unraveling the sexually dimorphic immune microenvironment in gastric cancer*
    Ryan Heslin, Ryan Heslin, University of Texas Southwestern Medical Center, Dallas, Texas
  • 10:55 a.m.| Neuroimmune dysregulation in ovarian cancer: The role of chronic stress on microglial activation and systemic inflammation*
    Luinet Melendez-Rodriguez, Ponce Health Sciences University, Coto Laurel, Puerto Rico
  • 11:10 a.m. | Comprehensive blood profiling for immunotherapy outcome prediction and longitudinal immune trajectory characterization*
    Max Emmerich, The Francis Crick Institute, London, United Kingdom

Plenary Session 10: Activity and Autoimmune Toxicity of Cancer Immunotherapy  

11:30 a.m.-1 p.m. | Grand Salon Opera AB

Session Chair: Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

  • 11:30 a.m. | Predicting, monitoring, and diagnosing immune-related adverse events
    David E. Gerber, University of Texas Southwestern Medical Center, Dallas, Texas 
  • 12 p.m. | Chloe Villani, Massachusetts General Hospital (MGH) Center for Cancer Research, Boston, Massachusetts
  • 12:30 p.m. | Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity*
    Cong Xing, UT Southwestern Medical Center, Dallas, Texas
  • 12:45 p.m. | nELISA high-throughput protein profiling applied to the RADIOHEAD cohort: insights from the largest plasma proteomics study of patients receiving checkpoint inhibitor therapy*
    Nathaniel Robichaud, Nomic Bio, Montreal, Quebec, Canada

Closing Remarks

1 p.m.